Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma – Jazz Pharmaceuticals

1. Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma  Jazz Pharmaceuticals
2. FDA Grants Accelerated Approval to Dordaviprone in Diffuse Midline Glioma  CancerNetwork
3. US FDA approves Jazz Pharma’s drug for rare brain tumor  Reuters
4. FDA Breakthrough: Jazz Pharma’s New Drug Targets Deadly Brain Tumor with No Previous Treatment  Stock Titan
5. FDA Approves Modeyso for Patients with Diffuse Midline Glioma  Curetoday

Continue Reading